Wegovy Weight Loss Injection UK - From £124.99 | Cured

Clinically Proven UK Registered Pharmacy

Cheapest Wegovy Weight Loss Injection UK Price - £124.99

Get genuine Wegovy at the cheapest UK price from £124.99 — Save £20 off with code Weightlossnew.

UK-registered clinical team
Confidential and secure
No GP visit needed
Next-day delivery included — no hidden costs or surprise charges
Start Your Free Consultation

Takes less than 2 minutes to complete 100% online

Weightlossnew £20 off for new customers

Treatment from £124.99

Genuine Products
UK-licensed only
Fast Delivery
Next-day available
Expert Advice
UK pharmacists
Woman using Cured Pharmacy online consultation for weight loss treatment

Check your BMI

Height 175 cm
Weight 82 kg

Your BMI

26.8
Start Free Consultation

Free · BMI thresholds shown are illustrative. Final eligibility is confirmed by a UK prescriber during your free consultation.

LIVE PRICING

Our Pricing

Pricing Disclaimer: Prices on some pages may not be up to date — the live pricing table below and pricing shown during consultation are official current prices and take precedence over any other figures on the site.

Mounjaro (Tirzepatide)
Weeks 1–4

2.5mg

1 pen • 4 Weeks

£145 £124.99

£31.25 / Per Week

Your starting dose – designed to help your body adjust gently to treatment

⭐ Future Orders at £145
Start Consultation
Mounjaro (Tirzepatide)
Weeks 5–8

5mg

1 pen • 4 Weeks

£179 £159.00

£39.75 / Per Week

First step up – builds on your progress as your body adapts to treatment

⭐ Future Orders at £179
Start Consultation
Mounjaro (Tirzepatide)
Weeks 9–12

7.5mg

1 pen • 4 Weeks

£220 £200.00

£50.00 / Per Week

Mid-range dose – for continued progression and enhanced results

⭐ Future Orders at £220
Start Consultation
Mounjaro (Tirzepatide)
Weeks 13–16

10mg

1 pen • 4 Weeks

£245 £225.00

£56.25 / Per Week

Higher strength dose – supports significant weight loss progress

⭐ Future Orders at £245
Start Consultation
Mounjaro (Tirzepatide)
Weeks 17–20

12.5mg

1 pen • 4 Weeks

£270 £250.00

£62.50 / Per Week

Advanced dose – for patients requiring stronger therapeutic effect

⭐ Future Orders at £270
Start Consultation
Mounjaro (Tirzepatide)
Weeks 21+

15mg

1 pen • 4 Weeks

£287 £267.00

£66.75 / Per Week

Maximum dose – the highest available strength for optimal results

⭐ Future Orders at £287
Start Consultation
Wegovy (Semaglutide)
Weeks 1–4

0.25mg

1 pen • 4 Weeks

£89 £69.00

£17.25 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £89
Start Consultation
Wegovy (Semaglutide)
Weeks 5–8

0.5mg

1 pen • 4 Weeks

£109 £89.00

£22.25 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £109
Start Consultation
Wegovy (Semaglutide)
Weeks 9–12

1mg

1 pen • 4 Weeks

£119 £99.00

£24.75 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £119
Start Consultation
Wegovy (Semaglutide)
Weeks 13–16

1.7mg

1 pen • 4 Weeks

£169 £149.00

£37.25 / Per Week

Higher strength – supports accelerated weight loss progress

⭐ Future Orders at £169
Start Consultation
Wegovy (Semaglutide)
Weeks 17+

2.4mg

1 pen • 4 Weeks

£199 £179.00

£44.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199
Start Consultation
Wegovy (Oral Pill)
Weeks 1–4

1.5mg

1 pen • 4 Weeks

£83.00 £63.00

£20.75 / Per Week

Your starting dose – eases your body into treatment with minimal side effects

⭐ Future Orders at £83.00
Start Consultation
Wegovy (Oral Pill)
Weeks 5–8

4mg

1 pen • 4 Weeks

£110.00 £90.00

£27.50 / Per Week

First step up – continues building tolerance for long-term success

⭐ Future Orders at £110.00
Start Consultation
Wegovy (Oral Pill)
Weeks 9–12

9mg

1 pen • 4 Weeks

£140.00 £120.00

£35.00 / Per Week

Mid-range dose – where most patients start seeing meaningful results

⭐ Future Orders at £140.00
Start Consultation
Wegovy (Oral Pill)
Weeks 13+

25mg

1 pen • 4 Weeks

£199.00 £179.00

£49.75 / Per Week

Maximum dose – the highest available strength for optimal weight management

⭐ Future Orders at £199.00
Start Consultation

Wegovy Weight Loss Injection: Clinical Evidence and UK Availability

Wegovy weight loss injection (semaglutide 2.4mg) represents a clinically proven GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Manufactured by Novo Nordisk and backed by the landmark STEP clinical trial programme, this once-weekly subcutaneous injection has demonstrated average weight reductions of 15-17% over 68 weeks when combined with lifestyle interventions [1]. As a prescription-only medicine dispensed by UK-registered pharmacies, Wegovy requires clinical assessment by a qualified prescriber to ensure suitability and safety.

How Wegovy Weight Loss Injection Works in the Body

Wegovy weight loss injection contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of naturally occurring GLP-1 hormones in the body. When administered subcutaneously once weekly, semaglutide binds to GLP-1 receptors in the brain's appetite regulation centres, particularly the hypothalamus, reducing hunger signals and increasing feelings of satiety after meals [2]. This mechanism differs fundamentally from stimulant-based appetite suppressants, as it works with the body's existing hormonal pathways rather than artificially stimulating the central nervous system.

The pharmacological action extends beyond appetite regulation. Clinical studies demonstrate that semaglutide slows gastric emptying, meaning food remains in the stomach longer, prolonging the sensation of fullness between meals [2]. Additionally, the medication influences reward pathways associated with food intake, potentially reducing cravings for high-calorie foods. The 2.4mg dose used in Wegovy represents the optimal therapeutic concentration identified through dose-ranging studies in the STEP trial programme, balancing efficacy with tolerability across diverse patient populations.

GLP-1 Receptor Mechanism and Metabolic Effects

Beyond weight reduction, Wegovy weight loss injection produces favourable metabolic effects documented in clinical trials. Patients typically experience improvements in glycaemic control, with reductions in HbA1c levels even in those without diabetes, alongside improvements in blood pressure and lipid profiles [1]. These cardiometabolic benefits contribute to the overall health improvements observed in clinical practice, though the primary indication remains weight management rather than diabetes treatment (for which lower semaglutide doses are prescribed under different brand names).

Clinical Evidence: STEP Trials for Wegovy Weight Loss Injection

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme provides the robust evidence base supporting Wegovy weight loss injection. The pivotal STEP 1 trial enrolled 1,961 adults with obesity or overweight with comorbidities, randomising participants to receive either semaglutide 2.4mg or placebo weekly for 68 weeks, alongside lifestyle interventions [1]. Results demonstrated that participants receiving Wegovy achieved an average weight loss of 14.9% of initial body weight, compared to 2.4% in the placebo group—a clinically and statistically significant difference that exceeded outcomes seen with previous weight management medications.

Subsequent STEP trials examined specific populations and scenarios. STEP 2 focused on individuals with type 2 diabetes, STEP 3 incorporated intensive behavioural therapy, and STEP 4 assessed weight maintenance after initial weight loss [3]. Across all trials, Wegovy weight loss injection consistently demonstrated superior efficacy compared to placebo, with approximately 85% of participants achieving at least 5% weight loss—the threshold associated with meaningful health improvements—and nearly 70% achieving 10% or greater weight reduction [3]. These outcomes positioned semaglutide 2.4mg as one of the most effective pharmacological interventions for obesity management currently available in the UK.

Wegovy Weight Loss Injection Dosing Schedule and Administration

Wegovy weight loss injection follows a graduated dose-escalation protocol designed to optimise gastrointestinal tolerability whilst achieving therapeutic effect. Treatment commences at 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [4]. This titration schedule, established through clinical trials, significantly reduces the incidence and severity of nausea and vomiting—the most common adverse effects associated with GLP-1 receptor agonists—by allowing the digestive system to adapt gradually to the medication's effects on gastric motility.

Each Wegovy weight loss injection is administered subcutaneously into the abdomen, thigh, or upper arm using a pre-filled FlexTouch pen supplied by Novo Nordisk. Patients receive comprehensive training on injection technique during their initial consultation, though the pen device is designed for intuitive self-administration. The once-weekly dosing schedule offers practical advantages over daily injections, improving adherence rates documented in real-world effectiveness studies [4]. Injections should occur on the same day each week, though the specific time of day is flexible—a feature that accommodates varying work schedules and lifestyles.

Storage and Handling Requirements

Proper storage maintains the stability and efficacy of Wegovy weight loss injection throughout its shelf life. Unused pens must be refrigerated at 2-8°C until first use, protected from light in the original carton. Once in use, pens may be stored at room temperature (below 30°C) or continued refrigeration for up to 6 weeks, offering flexibility for patients who travel or prefer not to inject cold medication [4]. Pens should never be frozen, and if freezing occurs, the medication must be discarded as freezing denatures the semaglutide protein structure.

Treatment Active Ingredient Frequency Starting Price
Wegovy Injection Semaglutide 2.4mg Once weekly from £89.00
Mounjaro Injection Tirzepatide Once weekly from £145.00
Saxenda Injection Liraglutide 3mg Once daily from £68.00

Who Can Use Wegovy Weight Loss Injection: Eligibility Criteria

Wegovy weight loss injection is licensed in the UK for adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea [5]. These criteria align with NICE guidance on pharmacological interventions for obesity management and reflect the populations studied in the STEP clinical trials. Prescribers assess individual suitability during clinical consultations, considering medical history, current medications, and contraindications before approving treatment.

Certain conditions preclude the use of Wegovy weight loss injection. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and hypersensitivity to semaglutide or excipients [5]. The medication is not recommended during pregnancy or breastfeeding, and women of childbearing potential should use effective contraception during treatment and for two months after discontinuation due to the long half-life of semaglutide. Patients with severe gastrointestinal disease, including gastroparesis, require careful evaluation as Wegovy affects gastric emptying. Those with a history of pancreatitis warrant particular caution, though the causal relationship between GLP-1 agonists and pancreatitis remains under investigation.

Side Effects and Safety Profile of Wegovy Weight Loss Injection

The most frequently reported side effects of Wegovy weight loss injection involve the gastrointestinal system, consistent with its mechanism of action on GLP-1 receptors in the digestive tract. In the STEP trials, nausea affected approximately 44% of participants, though this typically occurred during dose escalation and diminished over time [1]. Vomiting, diarrhoea, constipation, and abdominal discomfort represent other common gastrointestinal effects, generally mild to moderate in severity and transient in nature. The graduated dosing schedule specifically addresses these effects, allowing physiological adaptation before reaching therapeutic doses.

Less common but more serious adverse effects require awareness and monitoring. Wegovy weight loss injection carries warnings regarding potential thyroid C-cell tumours based on rodent studies, though human relevance remains uncertain and no causal link has been established in clinical use [5]. Acute pancreatitis has been reported rarely, presenting as persistent severe abdominal pain radiating to the back, and requires immediate discontinuation and medical evaluation. Hypoglycaemia may occur in patients taking concomitant antidiabetic medications, particularly insulin or sulphonylureas, necessitating dose adjustments of these agents. Gallbladder-related events, including cholelithiasis and cholecystitis, occur more frequently with substantial weight loss regardless of method, and patients should be counselled on recognising symptoms.

Managing Gastrointestinal Side Effects

Practical strategies can minimise gastrointestinal discomfort during Wegovy weight loss injection treatment. Eating smaller, more frequent meals rather than large portions reduces the sensation of fullness and associated nausea. Avoiding high-fat, fried, or heavily spiced foods during the initial weeks of treatment decreases digestive burden whilst the body adapts to slowed gastric emptying [6]. Staying well-hydrated and avoiding lying down immediately after eating further improves tolerability. If nausea persists despite these measures, prescribers may recommend temporarily maintaining the current dose for an additional week before escalating, or prescribing antiemetic medication for short-term symptom relief.

Purchasing Wegovy Weight Loss Injection from UK-Registered Pharmacies

Acquiring Wegovy weight loss injection legally in the UK requires a valid prescription issued by a registered healthcare professional following clinical assessment. At Cured Pharmacy, the process begins with a comprehensive online consultation reviewed by UK-registered prescribers who evaluate medical history, current medications, weight management goals, and suitability for semaglutide therapy. This assessment typically takes under three minutes to complete and ensures that treatment aligns with MHRA licensing and professional prescribing standards. Upon approval, genuine Novo Nordisk Wegovy is dispensed from our GPhC-registered pharmacy (9012511) with discreet next-day delivery across the UK.

Wegovy weight loss injection is available at Cured Pharmacy from £124.99 representing competitive UK pricing for this branded medication. Patients should be cautious of significantly lower prices that may indicate counterfeit or diverted medications—a growing concern with high-demand weight loss treatments. All Wegovy supplied through Cured Pharmacy is sourced through legitimate UK pharmaceutical supply chains, ensuring product authenticity, proper storage conditions, and full traceability. Our superintendent pharmacist, Tarun Kumar (GPhC 2233073), oversees dispensing procedures and remains available for clinical queries throughout your treatment journey. New patients can Save £20 on their first order using code Weightlossnew, reducing the initial cost whilst accessing genuine, MHRA-approved medication.

Verifying Pharmacy Legitimacy and Medication Authenticity

When purchasing Wegovy weight loss injection online, verification of pharmacy credentials protects against counterfeit products and substandard care. Legitimate UK pharmacies display their GPhC registration number prominently—ours is 9012511, verifiable on the General Pharmaceutical Council website. Genuine Wegovy pens feature specific packaging elements including Novo Nordisk branding, batch numbers, expiry dates, and holographic security features. The medication should arrive in temperature-controlled packaging if ambient temperatures exceed safe storage ranges, and include patient information leaflets in English conforming to UK regulatory requirements.

Scientific References

  1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 15 August 2026]
  2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
  3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & STEP 4 Investigators. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 15 August 2026]
  4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. [accessed 15 August 2026]
  5. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy (semaglutide): approved use for chronic weight management. Drug Safety Update, 16(9). [accessed 15 August 2026]
  6. Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., ... & Wilding, J. P. (2020). Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity, 28(6), 1050-1061. [accessed 15 August 2026]
  7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
  8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
  9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.

Trusted by thousands

Real people, real results

Jane L.

"Brilliant. Lost 4 stone on mounjaro no side effects at all. Cured pharmacy are excellent. Always helpful pens sent out quickly always comes with needles and sterile wipes. If you want to go on GLP-1 go to cured pharmacy. So professional. Thank you cured pharmacy you changed my health and well being."

Ann-Marie

"I absolutely love this product, I have been using 2.5mg as maintenance dose and have managed to control my weight without any side effects and can still eat well balanced meals. The pharmacy is very efficient friendly and helpful I would not purchase from anywhere else."

Sacha W.

"So far I'm really impressed by my results it's crazy cause I'm not snacking like how I used to do and I see my face slimming down already and it's only been 2 and a half weeks. Can't wait to give my feedback in 5 months time thank you cured pharmacy."

Kimberly G.

"Mounjaro has corrected my hormonal weight gain during menopause. I am using it now to maintain that balance. The results for me have been exceptional!"

Jennifer

"Great really helps cure those nasty habits can't wait for my next mounjaro pen."

How it Works?

Select from our recommended UK-licensed medications.

1

Choose your treatment

Step 1: Choose your treatment from Cured Pharmacy

Select safe UK treatments. Quick answers.

2

Answer quick questions

Step 2: Answer quick consultation questions

We will deliver direct to you as quickly as tomorrow.

3

Get it delivered fast

Step 3: Fast discreet delivery to your door

Start Your Assessment For Weight Loss

Start your journey to better health today.

  • Reviewed by UK-based prescribers
  • Takes under 3 minutes
  • Discreet Packaging

Start Your Journey To Better Health Today

Once you complete a short online assessment you will be able to choose your preferred treatment from safe medically approved options tailored to you.

Start My Assessment

Returning Customer?

Log in to Your Account

Faq

How quickly does Wegovy weight loss injection produce results?
Most patients notice appetite reduction within the first few weeks, with measurable weight loss typically becoming evident after 4-8 weeks of treatment. Maximum weight loss generally occurs around 60-68 weeks, though individual responses vary based on adherence, lifestyle modifications, and metabolic factors.
Can I use Wegovy weight loss injection if I have type 2 diabetes?
Yes, Wegovy is suitable for individuals with type 2 diabetes, and the STEP 2 trial specifically demonstrated efficacy in this population. However, dose adjustments to existing diabetes medications may be necessary to prevent hypoglycaemia, which your prescriber will manage during treatment.
What happens if I miss a dose of my Wegovy weight loss injection?
If fewer than 5 days have passed since your missed dose, administer it as soon as you remember, then resume your regular weekly schedule. If more than 5 days have passed, skip the missed dose and take your next injection on the regularly scheduled day to avoid potential side effects from dose stacking.
Do I need to follow a specific diet whilst using Wegovy weight loss injection?
Wegovy works most effectively alongside a reduced-calorie diet and increased physical activity, as implemented in the STEP clinical trials. Your prescriber or a registered dietitian can provide personalised nutritional guidance, though no specific diet plan is mandated—the medication helps reduce appetite naturally, making calorie reduction more achievable.
Is Wegovy weight loss injection available on the NHS?
NHS availability of Wegovy varies by region and clinical commissioning group, with many areas implementing restricted access due to budget constraints and supply considerations. Private prescriptions through registered UK pharmacies like Cured Pharmacy offer an alternative route to access this MHRA-licensed treatment subject to clinical suitability.
How long do I need to continue Wegovy weight loss injection treatment?
Treatment duration is individualised based on weight loss response and tolerability. Clinical guidelines suggest reassessing continuation at 6 months—if patients have not achieved at least 5% weight loss, discontinuation may be appropriate. Those responding well may continue treatment for extended periods to maintain weight loss, as weight regain commonly occurs after stopping.
Can Wegovy weight loss injection be used alongside other weight loss medications?
Wegovy should not be combined with other GLP-1 receptor agonists or weight loss medications without explicit prescriber guidance, as safety and efficacy of such combinations have not been established in clinical trials. Your prescriber will review all current medications during consultation to identify potential interactions or contraindications.
What makes Wegovy different from Ozempic if both contain semaglutide?
Wegovy weight loss injection contains semaglutide at a 2.4mg maintenance dose specifically licensed for chronic weight management, whereas Ozempic contains lower doses (0.5mg, 1mg, or 2mg) licensed exclusively for type 2 diabetes treatment. The pens, dosing schedules, and regulatory approvals differ, and using diabetes-licensed products for weight loss constitutes off-label use not covered by UK prescribing guidelines.
Tarun Kumar, Prescribing Pharmacist

Medically reviewed by

Tarun Kumar, Prescribing Pharmacist (GPhC 2233073)

Reviewed on: June 03, 2026

Last reviewed: 15 August 2026

Last updated on 15 August 2026.

Review History

Our experts continually monitor new findings in health and medicine, and we update our articles when new information becomes available.

Why this page was updated on 15 August 2026

Content checked and updated as part of our periodic review, to ensure accuracy and currentness.

Current version (15 August 2026)

Edited by: The Editorial Team

Medically reviewed by:

Tarun Kumar, GPhC No. 2233073, Prescribing Pharmacist


How we source info.

When we present you with stats, data, opinion or a consensus, we'll tell you where this came from.